Rasagiline and rapid symptomatic motor effect in Parkinson's disease: review of literature.

Neurol Ther · 2014 · PMC4381918 · PMID 26000219

Europe PMC DOI

hedged sentences

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

showed a trendP = 0.07so close (0.05 < p ≤ 0.1)

Quality of life, as measured by the PDQUALIF score, showed a trend toward improvement in patients treated with 0.5 mg/day rasagiline ( P = 0.07), but not with 1 mg/day rasagiline.

also in 53,322 other papers

did not reach statistical significanceno p-value reported

The increase in total effectiveness was not insignificant, with cost savings of €930 per treated patient, but this did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.